FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. (GILD) on Thursday reported third-quarter earnings of $3.05 billion.
On a per-share basis, the Foster City, California-based company said it had a profit of $2.43. Earnings, adjusted for one-time gains and costs, came to $2.47 per share. These results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $2.15 per share.
The HIV and hepatitis C drugmaker posted revenue of $7.77 billion in the period, which also topped Street forecasts. Seven analysts surveyed by Zacks had expected $7.46 billion.
Looking ahead, Gilead expects full-year earnings in the range of $8.05 to $8.25 per share, with revenue between $28.4 billion and $28.7 billion.
This story was generated by Automated Insights using data from Zacks Investment Research. Access a Zacks stock report on GILD at [link].
https://wtop.com/news/2025/10/gilead-q3-earnings-snapshot/